Economics of hematopoietic cell transplantation

Nandita D Khera, Steven B. Zeliadt, Stephanie J. Lee

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Given the rapidly rising healthcare costs, it is important to understand the economic costs of hematopoietic cell transplantation (HCT), a procedure that is being used more frequently in the treatment of various hematologic disorders. Studies have reported a wide range of costs for HCT, from $36 000 to $88 000 (USD) for a single autologous transplantation for the initial hospitalization, to $200 000 (USD) or more for a myeloablative allogeneic procedure involving an unrelated donor. Common posttransplantation complications, such as infections and GVHD, have been shown to be significant cost drivers. Comparisons across studies are limited by differences in patient populations, cost ascertainment methods, and length of follow-up. This article summarizes the current state of knowledge about costs and cost-effectiveness of HCT, highlighting the challenges in conducting these studies and identifying important areas for future research. We discuss the need for more value-based assessments of HCT using high-quality approaches to measuring costs and outcomes so that potential future efforts to contain costs are well informed and appropriate.

Original languageEnglish (US)
Pages (from-to)1545-1551
Number of pages7
JournalBlood
Volume120
Issue number8
DOIs
StatePublished - Aug 23 2012

Fingerprint

Cell Transplantation
Economics
Costs and Cost Analysis
Costs
Unrelated Donors
Autologous Transplantation
Health Care Costs
Cost effectiveness
Cost-Benefit Analysis
Hospitalization
Infection
Population

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Economics of hematopoietic cell transplantation. / Khera, Nandita D; Zeliadt, Steven B.; Lee, Stephanie J.

In: Blood, Vol. 120, No. 8, 23.08.2012, p. 1545-1551.

Research output: Contribution to journalArticle

Khera, Nandita D ; Zeliadt, Steven B. ; Lee, Stephanie J. / Economics of hematopoietic cell transplantation. In: Blood. 2012 ; Vol. 120, No. 8. pp. 1545-1551.
@article{4b21f2e6411b4721b5c3b6c8d266c4e6,
title = "Economics of hematopoietic cell transplantation",
abstract = "Given the rapidly rising healthcare costs, it is important to understand the economic costs of hematopoietic cell transplantation (HCT), a procedure that is being used more frequently in the treatment of various hematologic disorders. Studies have reported a wide range of costs for HCT, from $36 000 to $88 000 (USD) for a single autologous transplantation for the initial hospitalization, to $200 000 (USD) or more for a myeloablative allogeneic procedure involving an unrelated donor. Common posttransplantation complications, such as infections and GVHD, have been shown to be significant cost drivers. Comparisons across studies are limited by differences in patient populations, cost ascertainment methods, and length of follow-up. This article summarizes the current state of knowledge about costs and cost-effectiveness of HCT, highlighting the challenges in conducting these studies and identifying important areas for future research. We discuss the need for more value-based assessments of HCT using high-quality approaches to measuring costs and outcomes so that potential future efforts to contain costs are well informed and appropriate.",
author = "Khera, {Nandita D} and Zeliadt, {Steven B.} and Lee, {Stephanie J.}",
year = "2012",
month = "8",
day = "23",
doi = "10.1182/blood-2012-05-426783",
language = "English (US)",
volume = "120",
pages = "1545--1551",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Economics of hematopoietic cell transplantation

AU - Khera, Nandita D

AU - Zeliadt, Steven B.

AU - Lee, Stephanie J.

PY - 2012/8/23

Y1 - 2012/8/23

N2 - Given the rapidly rising healthcare costs, it is important to understand the economic costs of hematopoietic cell transplantation (HCT), a procedure that is being used more frequently in the treatment of various hematologic disorders. Studies have reported a wide range of costs for HCT, from $36 000 to $88 000 (USD) for a single autologous transplantation for the initial hospitalization, to $200 000 (USD) or more for a myeloablative allogeneic procedure involving an unrelated donor. Common posttransplantation complications, such as infections and GVHD, have been shown to be significant cost drivers. Comparisons across studies are limited by differences in patient populations, cost ascertainment methods, and length of follow-up. This article summarizes the current state of knowledge about costs and cost-effectiveness of HCT, highlighting the challenges in conducting these studies and identifying important areas for future research. We discuss the need for more value-based assessments of HCT using high-quality approaches to measuring costs and outcomes so that potential future efforts to contain costs are well informed and appropriate.

AB - Given the rapidly rising healthcare costs, it is important to understand the economic costs of hematopoietic cell transplantation (HCT), a procedure that is being used more frequently in the treatment of various hematologic disorders. Studies have reported a wide range of costs for HCT, from $36 000 to $88 000 (USD) for a single autologous transplantation for the initial hospitalization, to $200 000 (USD) or more for a myeloablative allogeneic procedure involving an unrelated donor. Common posttransplantation complications, such as infections and GVHD, have been shown to be significant cost drivers. Comparisons across studies are limited by differences in patient populations, cost ascertainment methods, and length of follow-up. This article summarizes the current state of knowledge about costs and cost-effectiveness of HCT, highlighting the challenges in conducting these studies and identifying important areas for future research. We discuss the need for more value-based assessments of HCT using high-quality approaches to measuring costs and outcomes so that potential future efforts to contain costs are well informed and appropriate.

UR - http://www.scopus.com/inward/record.url?scp=84865402362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865402362&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-05-426783

DO - 10.1182/blood-2012-05-426783

M3 - Article

C2 - 22700725

AN - SCOPUS:84865402362

VL - 120

SP - 1545

EP - 1551

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -